Patents Assigned to Checkpoint Therapeutics, Inc.
  • PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20240150468
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: Checkpoint Therapeutics, Inc.
    Inventors: Jonathan BELK, Nathan J. SHARKEY, Leonid GORELIK
  • PD-L1-specific antibodies and methods of using the same
    Patent number: 11834505
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 5, 2023
    Assignee: Checkpoint Therapeutics, Inc.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20200277380
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 3, 2020
    Applicant: Checkpoint Therapeutics Inc.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • PD-L1-specific antibodies and methods of using the same
    Patent number: 10590199
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 17, 2020
    Assignee: CHECKPOINT THERAPEUTICS, INC.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20180002424
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 4, 2018
    Applicant: Checkpoint Therapeutics, Inc.
    Inventors: Jonathan BELK, Nathan J. Sharkey, Leonid Gorelik